https://www.biospace.com/allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - BioSpace
Jun 2, 2020 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price...
allogene therapeuticspublic offeringcommon stockannouncespricing
https://finbold.com/guide/how-to-buy-allogene-therapeutics-stock/
How to Buy Allogene Therapeutics Stock [2026] | Invest in ALLO
Dec 30, 2025 - In this step-by-step guide, you will learn how to buy Allogene Therapeutics stock conveniently, securely, and fast.
how to buyallogene therapeuticsinvest instock2026
https://www.home.saxo/pl-pl/markets/stocks/allo-xnas
Allogene Therapeutics Inc. akcja | Saxo Bank
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates...
allogene therapeuticsincakcjasaxobank
https://www.ig.com/za/shares/markets-shares/allogene-therapeutics-inc
Trade Allogene Therapeutics Inc Shares | Live Allogene Therapeutics Inc Share Price | IG South...
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered... [ZA]
live share priceallogene therapeuticstradeincshares
https://www.globenewswire.com/news-release/2019/02/20/1738330/0/en/Allogene-Therapeutics-Enters-Lease-to-Build-Manufacturing-Facility-to-Develop-and-Commercialize-Allogeneic-CAR-T-AlloCAR-T-Therapies.html?culture=en-us
Allogene Therapeutics Enters Lease to Build Manufacturing
State-of-the-Art Manufacturing Facility to be Located in the San Francisco East Bay AreaAllogene Committed to Advanced Cell Manufacturing for Long-Term...
allogene therapeuticsto buildentersleasemanufacturing
https://www.fool.com/investing/2020/05/14/heres-why-allogene-therapeutics-is-roaring-higher.aspx
Here's Why Allogene Therapeutics Is Roaring Higher Today | The Motley Fool
May 14, 2020 - The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.
here sallogene therapeutics
https://www.macrotrends.net/stocks/charts/ALLO/allogene-therapeutics/stock-splits
Allogene Therapeutics - 8 Year Stock Split History | ALLO | MacroTrends
Stock split history for Allogene Therapeutics since 2018. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please...
stock split historyallogene therapeutics8yearmacrotrends
https://www.biospace.com/allogene-therapeutics-announces-participation-in-november-investor-conferences
Allogene Therapeutics Announces Participation in November Investor Conferences - BioSpace
Oct 30, 2023 - Allogene Therapeutics, Inc. today announced that it will participate in two upcoming investor conferences in November.
allogene therapeuticsin novemberinvestor conferencesannouncesparticipation
https://www.ig.com/ae/shares/markets-shares/allogene-therapeutics-inc
Trade Allogene Therapeutics Inc Shares | Live Allogene Therapeutics Inc Share Price | IG Dubai | IG...
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered... [AE]
live share priceallogene therapeuticstradeincshares
https://www.ig.com/fr-ch/actions/marches-actions/allogene-therapeutics-inc
Action Allogene Therapeutics Inc | Cours Allogene Therapeutics Inc | Allogene Therapeutics Inc | IG...
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered... [FR-CH]
allogene therapeuticsactioninccoursig
https://www.ig.com/sg/shares/markets-shares/allogene-therapeutics-inc
Trade Allogene Therapeutics Inc Shares | Live Allogene Therapeutics Inc Share Price | IG Singapore...
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered... [SG]
live share priceallogene therapeuticstradeincshares
https://www.biospace.com/allogene-therapeutics-announces-eric-t-schmidt-ph-d-as-chief-financial-officer
Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer - BioSpace
Jun 18, 2018 - Dr. Schmidt comes to Allogene from Cowen and Company, where he served as Managing Director and Senior Biotechnology Analyst since 1998
https://www.goldmansachs.com/insights/talks-at-gs/arie-belldegrun
Dr. Arie Belldegrun, Co-Founder and Executive Chairman, Allogene Therapeutics | Goldman Sachs
arie belldegrunco founder
https://www.biospace.com/allogene-therapeutics-presents-updated-allo-501-501a-phase-1-data-in-large-b-cell-lymphoma-at-the-american-society-of-clinical-oncology-asco-annual-meeting
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the...
Jun 5, 2023 - Allogene Therapeutics, Inc. presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory large...
https://www.benzinga.com/analyst-ratings/21/10/23339673/what-5-analyst-ratings-have-to-say-about-allogene-therapeutics
What 5 Analyst Ratings Have To Say About Allogene Therapeutics - Allogene Therapeutics...
Oct 12, 2021 - Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:
have to sayanalyst ratings5therapeutics
https://finviz.com/news/47943/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Stock screener for investors and traders, financial visualizations.
https://www.biospace.com/press-releases/allogene-therapeutics-announces-benjamin-m-beneski-as-senior-vice-president-and-chief-technical-officer
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical...
senior vice president
https://www.biospace.com/allogene-therapeutics-presents-preclinical-data-on-allo-316-in-acute-myeloid-leukemia-at-the-62nd-meeting-of-the-american-society-of-hematology
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd...
Dec 7, 2020 - Investigational New Drug (IND) Application for ALLO-316 Cleared by U.S. Food and Drug Administration (FDA); Phase 1 Trial in RCC to Start in 2021